Since its outbreak in China in December 2019 a novel Coronavirus, named SARS-CoV-2, has spread worldwide causing many cases of severe pneumonia, referred to as COVID-19 disease, leading the World Health Organization to declare a pandemic emergency in March 2020 . Up to now, no specific therapy against COVID-19 disease exists . This paper aims to review COVID-19 treatment options currently under investigation . We divided the studied drugs into three categories (antiviral, immunomodulatory and other drugs). For each molecule, we discussed the putative mechanisms by which the drug may act against SARS-CoV-2 or may affect COVID-19 pathogenesis and the main clinical studies performed so far . The published clinical studies suffer from methodological limitations due to the emergency setting in which they have been conducted . Nevertheless, it seems that the timing of administration of the diverse categories of drugs is crucial in determining clinical efficacy . Antiviral drugs, in particular Remdesivir, should be administered soon after symptoms onset, in the viraemic phase of the disease; whereas, immunomodulatory agents, such as tocilizumab, anakinra and steroids, may have better results if administered in pneumonia/hyperinflammatory phases . Low-molecular-weight heparin may also have a role when facing COVID-19-related coagulopathy . Up to now, treatment choices have been inferred from the experience with other coronaviruses or viral infection outbreaks . Hopefully, in the near future, new treatment strategies will be available thanks to increased knowledge on SARS-CoV2 virus and COVID-19 pathogenesis . In the meanwhile, further well-designed clinical trials are urgently needed to establish a standard of care in COVID-19 disease.